SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hanna Michael G.)
 

Sökning: WFRF:(Hanna Michael G.) > (2020-2022) > (2021) > Uppsala universitet > NT-proBNP for Risk ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007488naa a2200805 4500
001oai:DiVA.org:uu-456183
003SwePub
008211015s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4561832 URI
0247 a https://doi.org/10.1016/j.jchf.2021.05.0142 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Vergaro, Giuseppeu Scuola Super Sant Anna, Pisa, Italy; Fdn Toscana G Monasterio, Pisa, Italy4 aut
2451 0a NT-proBNP for Risk Prediction in Heart Failure :b Identification of Optimal Cutoffs Across Body Mass Index Categories
264 1b American College of Cardiology,c 2021
338 a print2 rdacarrier
520 a ObjectivesThe goal of this study was to assess the predictive power of N-terminal pro–B-type natriuretic peptide (NT-proBNP) and the decision cutoffs in heart failure (HF) across body mass index (BMI) categories.BackgroundConcentrations of NT-proBNP predict outcome in HF. Although the influence of BMI to reduce levels of NT-proBNP is known, the impact of obesity on prognostic value remains uncertain.MethodsIndividual data from the BIOS (Biomarkers In Heart Failure Outpatient Study) consortium were analyzed. Patients with stable HF were classified as underweight (BMI <18.5 kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2), and mildly (BMI 30-34.9 kg/m2), moderately (BMI 35-39.9 kg/m2), or severely (BMI ≥40 kg/m2) obese. The prognostic role of NT-proBNP was tested for the endpoints of all-cause and cardiac death.ResultsThe study population included 12,763 patients (mean age 66 ± 12 years; 25% women; mean left ventricular ejection fraction 33% ± 13%). Most patients were overweight (n = 5,176), followed by normal weight (n = 4,299), mildly obese (n = 2,157), moderately obese (n = 612), severely obese (n = 314), and underweight (n = 205). NT-proBNP inversely correlated with BMI (β = –0.174 for 1 kg/m2; P < 0.001). Adding NT-proBNP to clinical models improved risk prediction across BMI categories, with the exception of severely obese patients. The best cutoffs of NT-proBNP for 5-year all-cause death prediction were lower as BMI increased (3,785 ng/L, 2,193 ng/L, 1,554 ng/L, 1,045 ng/L, 755 ng/L, and 879 ng/L, for underweight, normal weight, overweight, and mildly, moderately, and severely obese patients, respectively) and were higher in women than in men.ConclusionsNT-proBNP maintains its independent prognostic value up to 40 kg/m2 BMI, and lower optimal risk-prediction cutoffs are observed in overweight and obese patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a body mass index
653 a chronic heart failure
653 a NT-proBNP
653 a obesity
653 a outcome
7001 a Gentile, Francescou Fdn Toscana G Monasterio, Pisa, Italy4 aut
7001 a Meems, Laura M. G.u Univ Med Ctr Groningen, Groningen, Netherlands4 aut
7001 a Aimo, Albertou Scuola Super Sant Anna, Pisa, Italy4 aut
7001 a Januzzi Jr., James L.u Massachusetts Gen Hosp, Boston, MA 02114 USA; Baim Inst Clin Res, Boston, MA USA4 aut
7001 a Richards, A. Marku Univ Otago, Dunedin, New Zealand4 aut
7001 a Lam, Carolyn S. P.u Natl Heart Ctr Singapore, Singapore, Singapore; Duke Natl Univ Singapore, Singapore, Singapore4 aut
7001 a Latini, Robertou IRCCS Milano, IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy4 aut
7001 a Staszewsky, Lidiau IRCCS Milano, IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy4 aut
7001 a Anand, Inder S.u Univ Minnesota, Minneapolis, MN USA; VA Med Ctr, Minneapolis, MN USA4 aut
7001 a Cohn, Jay N.u Univ Minnesota, Minneapolis, MN USA4 aut
7001 a Ueland, Thoru Oslo Univ Hosp, Oslo, Norway; Oslo Univ Hosp, Rigshosp, Oslo, Norway; Univ Oslo, Oslo, Norway; Univ Tromso, Tromso, Norway4 aut
7001 a Gullestad, Larsu Univ Oslo, KG Jebsen Ctr Cardiac Res, Oslo, Norway; Oslo Univ Hosp, Ctr Heart Failure Res, Oslo, Norway4 aut
7001 a Aukrust, Pålu Oslo Univ Hosp, Rigshosp, Oslo, Norway; Univ Oslo, Oslo, Norway4 aut
7001 a Brunner-La Rocca, Hans-Peteru Maastricht Univ, Med Ctr, Maastricht, Netherlands4 aut
7001 a Bayes-Genis, Antoniu Hosp Badalona Germans Trias & Pujol, Badalona, Barcelona, Spain; Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain4 aut
7001 a Lupón, Josepu Hosp Badalona Germans Trias & Pujol, Badalona, Barcelona, Spain; Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain4 aut
7001 a Yoshihisa, Akiomiu Fukushima Med Univ, Fukushima, Japan4 aut
7001 a Takeishi, Yasuchikau Fukushima Med Univ, Fukushima, Japan4 aut
7001 a Egstrup, Michaelu Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark4 aut
7001 a Gustafsson, Idau Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark4 aut
7001 a Gaggin, Hanna K.u Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA 02115 USA4 aut
7001 a Eggers, Kai M.,d 1962-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)kaieg561
7001 a Huber, Kurtu Wilhelminenspital Stadt Wien, Vienna, Austria; Sigmund Freud Univ, Med Sch, Vienna, Austria4 aut
7001 a Gamble, Greg D.u Univ Auckland, Auckland, New Zealand4 aut
7001 a Ling, Lieng H.u Natl Univ Heart Ctr, Singapore, Singapore; Natl Univ Singapore, Singapore, Singapore4 aut
7001 a Leong, Kui Tong Gerardu Changi Gen Hosp, Singapore, Singapore4 aut
7001 a Yeo, Poh Shuah Danielu Tan Tock Seng Hosp, Singapore, Singapore4 aut
7001 a Ong, Hean Yeeu Khoo Teck Puat Hosp, Singapore, Singapore4 aut
7001 a Jaufeerally, Fazluru Singapore Gen Hosp, Singapore, Singapore4 aut
7001 a Ng, Tze P.u Natl Univ Heart Ctr, Singapore, Singapore; Natl Univ Singapore, Singapore, Singapore4 aut
7001 a Troughton, Richardu Massachusetts Gen Hosp, Boston, MA 02114 USA; Baim Inst Clin Res, Boston, MA USA4 aut
7001 a Doughty, Robert N.u Univ Auckland, Auckland, New Zealand4 aut
7001 a Devlin, Gerryu Gisborne Hosp, Gisborne, New Zealand4 aut
7001 a Lund, Mayannau Middlemore Hosp, Auckland, New Zealand4 aut
7001 a Giannoni, Albertou Scuola Super Sant Anna, Pisa, Italy; Fdn Toscana G Monasterio, Pisa, Italy4 aut
7001 a Passino, Claudiou Scuola Super Sant Anna, Pisa, Italy; Fdn Toscana G Monasterio, Pisa, Italy4 aut
7001 a Boer, Rudolf A. deu Univ Med Ctr Groningen, Groningen, Netherlands4 aut
7001 a Emdin, Micheleu Scuola Super Sant Anna, Pisa, Italy; Fdn Toscana G Monasterio, Pisa, Italy4 aut
7102 a Scuola Super Sant Anna, Pisa, Italy; Fdn Toscana G Monasterio, Pisa, Italyb Fdn Toscana G Monasterio, Pisa, Italy4 org
7730 t JACC. Heart failured : American College of Cardiologyg 9:9, s. 653-663q 9:9<653-663x 2213-1779x 2213-1787
8564 u https://pure.rug.nl/ws/files/181603022/NT_proBNP_for_Risk_Prediction_in_Heart_nbsp_Failure.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456183
8564 8u https://doi.org/10.1016/j.jchf.2021.05.014

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy